Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4836884 | 0.99 | ALDH1A1 (0.54) | ALDH1A1KMT2ADRD2SIGMAR1HTR7 | |
| SCHEMBL4838738 | 0.91 | KMT2A (0.49) | ALDH1A1KMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL4831071 | 0.90 | KMT2A (0.48) | ALDH1A1KMT2ATACR1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL4831009 | 0.90 | KMT2A (0.48) | ALDH1A1KMT2ATACR1SMN1; SMN2LMNA | |
| SCHEMBL4836256 | 0.90 | KMT2A (0.48) | ALDH1A1KMT2ATACR1SMN1; SMN2LMNA | |
| SCHEMBL4836644 | 0.89 | TACR1 (0.49) | ALDH1A1KMT2ATACR1SMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL4827786 | 0.89 | KMT2A (0.47) | ALDH1A1KMT2ATACR1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL4835344 | 0.88 | TACR1 (0.48) | ALDH1A1KMT2ATACR1SMN1; SMN2MAPK1 | |
| SCHEMBL4831054 | 0.88 | KMT2A (0.44) | ALDH1A1KMT2AMEN1TACR1SMN1; SMN2 | |
| SCHEMBL4828017 | 0.87 | CCR2 (0.52) | ALDH1A1KMT2AMEN1TACR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | claimed |
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | ALDH1A1 1168/4885KMT2A 4243/4885DRD2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.